3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Ovarian Neoplasms
2
Non Small Cell Lung Carcinoma NSCLC
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Triple Negative Breast Neoplasms
1
Ovarian Diseases
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Endocrine System Diseases
1
Carcinoma, Ovarian Epithelial
1
Breast Neoplasms
1
Interventions
Carboplatin
25
Paclitaxel
24
pembrolizumab
22
Cyclophosphamide
14
Gemcitabine
10
Capecitabine
10
Doxorubicin
9
Specimen Handling
8
Nivolumab
8
Taxes
7
Magnetic Resonance Spectroscopy
7
sacituzumab govitecan
6
olaparib
6
Cisplatin
6
eribulin
5
durvalumab
5
atezolizumab
5
Radiotherapy
5
Albumin-Bound Paclitaxel
5
130-nm albumin-bound paclitaxel
5
capivasertib
4
Epirubicin
4
Docetaxel
4
Biopsy
4
niraparib
3
Vinorelbine
3
Radiation
3
Fulvestrant
3
Blood Specimen Collection
3
trastuzumab deruxtecan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Triple Negative Breast Neoplasms
×
CP protocol
×
Clear all
NCT03168880
2025-04-09
TNBC
Tata Memorial Hospital
Phase 3
Active not recruiting
720 enrolled